Exploratory analysis of eating-and physical activity-related outcomes from a randomized controlled trial for weight loss maintenance with exercise and liraglutide single or combination treatment
Open accessThe DOI matches its Crossref record; the references it cites are not checked yet; 14 of the 35 sources its claims cite were checked for support.
Abstract
Weight regain after weight loss remains a major challenge in obesity treatment and may involve alteration of eating and sedentary behavior after weight loss. In this randomized, controlled, double-blind trial, adults with obesity were randomized, in a 1:1:1:1 ratio stratified by sex and age group (<40 years and ≥40 years), to one-year weight loss maintenance with exercise, the GLP-1 receptor agonist liraglutide, or the combination, as compared with placebo, after low-calorie diet-induced weight loss. Primary outcome was change in body weight, which has been published. Here, we investigated the effects of weight loss maintenance with exercise, liraglutide, or the combination on weight loss-induced changes in the pre-specified explorative outcomes, eating and sedentary behavior in 130 participants who completed the trial according to the study protocol (exercise (n = 26), liraglutide (n = 36), combination (n = 29), and placebo (n = 39)). One year after weight loss, the placebo group had decreased postprandial appetite suppression score by 14%, and increased sedentary time by 31 min/day and regained weight. Liraglutide prevented the decrease in postprandial appetite suppression score compared with placebo (0% vs. −14%; P = 0.023) and maintained weight loss. Exercise after weight loss did not increase appetite or sedentary behavior compared with placebo, despite increased exercise energy expenditure and maintained weight loss. The combination of exercise and liraglutide increased cognitive restraint score (13% vs. −9%; P = 0.042), reflecting a conscious restriction of food intake, and decreased sedentary time by 41 min/day (−10 vs. 31 min/day; 95%CI, −82.3 to −0.2; P = 0.049) compared with placebo, which may have facilitated the additional weight loss. Targeting both eating and sedentary behavior could be the most effective for preventing weight regain. Trial registration: EudraCT number, 2015-005585-32; clinicaltrials.gov number, NCT04122716.
Overview
CoChat Summary
TL;DR
In a one-year randomized trial after diet-induced weight loss, placebo was associated with increased appetite and sedentary time and weight regain, while liraglutide prevented the appetite increase and exercise did not further increase appetite despite higher exercise energy expenditure. Combining exercise and liraglutide improved cognitive restraint and reduced sedentary time, and this combination produced the greatest additional weight loss.
Key findings
- In the per-protocol population (n = 130), placebo regained 6.1 kg after the initial 13.7 kg diet-induced weight loss, had a 14% decrease in postprandial appetite suppression score, and increased accelerometer-measured sedentary time by 31 min/day.
- Liraglutide prevented the decrease in postprandial appetite suppression score (0% vs. −14%; P = 0.023) and maintained weight loss (−1.9 kg; difference from placebo, −8.0 kg; 95% CI, −11.7 to −4.2).
- Exercise did not increase appetite or sedentary behavior compared with placebo despite increased exercise energy expenditure (1661 ± 738 kcal/week in the exercise group) and maintained weight loss (0.7 kg; difference from placebo, −5.3 kg; 95% CI, −9.4 to −1.2).
- The combination of exercise and liraglutide increased cognitive restraint score (13% vs. −9%; P = 0.042), decreased sedentary time by 41 min/day (−10 vs. 31 min/day; 95% CI, −82.3 to −0.2; P = 0.049), and produced additional weight loss (−6.0 kg; difference from placebo, −12.1 kg; 95% CI, −16.1 to −8.1).
Methods
- Randomized, double-blind, placebo-controlled 2-by-2 factorial trial in adults aged 18–65 years with obesity (BMI 32–43 kg/m²) without diabetes; after an 8-week ~800 kcal/day low-calorie diet, participants with ≥5% weight loss were randomized 1:1:1:1, stratified by sex and age group, to exercise + placebo, liraglutide 3.0 mg/day, combination, or placebo for one year.
- Eating behavior was assessed with the Three-Factor Eating Questionnaire-R18; appetite with visual analog scale ratings during a 3-hour mixed meal; food preferences with the Leeds Food Preference Questionnaire; sedentary behavior and physical activity with 7-day wrist-worn accelerometry and the IPAQ-SF; exercise energy expenditure with Polar sports watches.
- Changes were analyzed with linear mixed models including time, group, sex, age group, and time–group interaction, in per-protocol and intention-to-treat populations; multiple regression tested associations between behavioral changes and weight change, with analyses described as exploratory and unadjusted for multiplicity.
Limitations
- The authors state they cannot prove causal inferences that the measured outcomes are the reason for the weight changes, although this seems probable.
- The per-protocol analysis may introduce subset selection bias that cannot be distinguished from the treatment effect; intention-to-treat analyses generally showed the same picture.
- The analyses were exploratory and unadjusted for multiplicity, so definite inferences cannot be made; additionally, wrist-worn accelerometry was not expected to detect the stationary-bike exercise, so self-reported physical activity was also used.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 Changes in postprandial appetite suppression and eating behavior during the study. Violin plots of observed changes in a postprandial appetite suppression score, b cognitive restraint, c emotional eating, and d uncontrolled eating. Changes are from week −8 to week 0 (low-calorie diet, yellow color in grey shaded area, n = 130) for all groups combined and from week 0 to week 52 (after randomization) in the four groups, separately: placebo (grey color, n = 39), exercise (green color, n = 26), liraglutide (blue color, n = 36), and the combination of liraglutide and exercise (red color, n = 29). The diamonds indicate observed means and the dots indicate individual observations. The appetite suppression score was calculated as (satiety + fullness + [100 – hunger] + [100 – prospective food consumption])/4; all were subjective ratings (180 min area under the curve from visual analogue scales. Cognitive restraint, emotional eating, and uncontrolled eating scores were measured on a 0–100 scale by Three-Factor Eating Questionnaire-R18. Results are presented for study participants who adhered to the study interventions (per protocol population). P-values are provided for significant (P < 0.05) differences from the placebo group. P-values are two-sided and unadjusted for multiple comparisons and derived from a mixed model analysis as described in statistical analyses. Source data are provided as a Source Data file.](https://figures.cochat.ai/paper-figures/dc386c94e1374ba8a50fa109a026db77/exploratory-analysis-of-eating-and-physical-activity-related-outcomes-from-a-figure-1.jpg)


Verification
Claims the paper makes
7 Valid · 2 Not valid · 10 Not checked · 84 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Weight loss was maintained in the exercise group with a treatment effect of −5.3 kg compared with placebo26.”
§ Exploratory analysis of eating- and physical activity-related outcomes from a randomized controlled trial for weight loss maintenance with exercise and liraglutide single or combination treatment > Discussion
What the sources say
- Disputedcites [26] Lundgren, J. R. et al. Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined. N. Engl. J. Med 384, 1719–30 (2021). sourceExperimental — accuracy not yet measured
Our copy states the exercise-versus-placebo comparison explicitly but with a different magnitude: the Body Weight and Body-Fat Percentage section reports 'The initial weight loss was maintained in the exercise group, with a treatment effect as compared with placebo of -4.1 kg (95% CI, -7.8 to -0.4; P = 0.03)', and the RESULTS section repeats the -4.1 kg difference. The only values near -5.3 kg in the paper are the combination-vs-exercise difference (-5.4 kg; 95% CI, -9.0 to -1.7; P = 0.004) and the liraglutide-vs-placebo effect (-6.8 kg), so the -5.3 kg attributed to exercise versus placebo is contrary to what the source reports. (LLM, conf=0.78)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“The combination group had a substantial weight reduction of −12.1 kg compared with placebo26, which might in itself increase appetite6.”
§ Exploratory analysis of eating- and physical activity-related outcomes from a randomized controlled trial for weight loss maintenance with exercise and liraglutide single or combination treatment > Discussion
What the sources say
- Disputedcites [26] Lundgren, J. R. et al. Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined. N. Engl. J. Med 384, 1719–30 (2021). sourceExperimental — accuracy not yet measured
Our copy states the combination-vs-placebo between-group difference in body weight at 1 year as -9.5 kg (95% CI, -13.1 to -5.9; P<0.001) in both the RESULTS section and the 'Body Weight and Body-Fat Percentage' subsection (where it is derived as -3.4 kg further loss in combination vs +6.1 kg regain in placebo), not -12.1 kg. Searching for '12.1' and for total weight change from before the low-calorie diet returned no such figure anywhere in our copy; the only nearby numbers are the -13.1 kg mean decrease during the 8-week low-calorie diet and the lower CI bound of -13.1 kg. So the direction (combination group lost substantially more than placebo) is right, but the magnitude attributed to this trial contradicts the value the paper reports. (LLM, conf=0.82)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Disputed
Every source the paper cites for this claim was checked and supports it.
In the paper
“The combination group had a substantial weight reduction of −12.1 kg compared with placebo26, which might in itself increase appetite6.”
§ Exploratory analysis of eating- and physical activity-related outcomes from a randomized controlled trial for weight loss maintenance with exercise and liraglutide single or combination treatment > Discussion
What the sources say
- Supportedcites [6] Nymo, S. et al. Investigation of the long-term sustainability of changes in appetite after weight loss. Int J. Obes. 42, 1489–1499 (2018). source
The Introduction says weight loss is associated with increased hunger, and the Discussion reports increased hunger after substantial weight loss. The citing sentence says the combination group’s weight reduction might increase appetite; it does not attribute that group’s specific −12.1 kg result to this source. (LLM, conf=0.90)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The liraglutide group also tended to have a higher cognitive restraint score than the placebo group (8.3% vs. −8.6%; P = 0.07)”
§ Exploratory analysis of eating- and physical activity-related outcomes from a randomized controlled trial for weight loss maintenance with exercise and liraglutide single or combination treatment > Results > The combination of liraglutide and exercise improves cognitive restraint and reduces sedentary time during weight maintenance
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“One year after randomization, the combination group exhibited a higher cognitive restraint score than the placebo group (12.8% vs. −8.6%; P = 0.04).”
§ Exploratory analysis of eating- and physical activity-related outcomes from a randomized controlled trial for weight loss maintenance with exercise and liraglutide single or combination treatment > Results > The combination of liraglutide and exercise improves cognitive restraint and reduces sedentary time during weight maintenance
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
56 more claims
Create a free account to see all 103 claims and to verify the 21 references still open.
- Probably not a substantial claim. 19
- It may state two separate claims as one. 31
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“GLP-1 receptor agonists induce weight loss primarily due to reduced appetite and, consequently, reduced food intake.5,6”
From Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment: a post-treatment analysis of a randomised placebo-controlled trial (2024) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“GLP-1 receptor agonists induce weight loss primarily by appetite inhibition5,6,36 and slowed gastric emptying,37 and have been shown to improve eating behaviours, i.e., reduce uncontrolled and emotional eating and improve cognitive restraint.6,38”
From Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment: a post-treatment analysis of a randomised placebo-controlled trial (2024) · cites this paper as [6]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Both cognitive restraint and moderate to vigorous physical activity were associated with less weight regain.”
From Incretin-Based Weight Loss Pharmacotherapy: Can Resistance Exercise Optimize Changes in Body Composition? (2024) · cites this paper as [78]
The cited source says what the claim attributes to it.
In the citing paper
“Liraglutide counteracts the increased appetite after weight loss, and with exercise improves cognitive restraint and reduces sedentary time, helping to prevent weight regain.40,54”
From GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review (2024) · cites this paper as [54]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“| OAS score (180 min x mm) | 395 (9; 782) | −1322 (−2128; −516) | −1310 (−2117; −503) | −122 (−890; 646) | −1154 (−1905; 403) |”
§ Exploratory analysis of eating- and physical activity-related outcomes from a randomized controlled trial for weight loss maintenance with exercise and liraglutide single or combination treatment > Results > The GLP-1RA liraglutide counteracts the increased appetite during weight loss maintenance
Reported -1154 · recomputed -751
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“| High fat sweet, Implicit wanting (no unit) | −9.8 (−14.1; 5.4) | 6.7 (1.5; 12.0) | 7.2 (0.6; 13.7) | 3.0 (−2.5; 8.5) | 2.3 (−3.8; 8.4) |”
§ Exploratory analysis of eating- and physical activity-related outcomes from a randomized controlled trial for weight loss maintenance with exercise and liraglutide single or combination treatment > Results > Weight loss is associated with increased appetite and sedentary time that persist after one year
Reported -9.8 · recomputed -4.35
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“| High fat sweet, Implicit wanting (no unit) | −9.4 (−12.7; 6.1) | 7.0 (1.8; 12.3) | 8.1 (2.6; 13.6) | 2.3 (−2.9; 7.4) | 2.7 (−2.3; 7.7) |”
§ Exploratory analysis of eating- and physical activity-related outcomes from a randomized controlled trial for weight loss maintenance with exercise and liraglutide single or combination treatment > Results > The GLP-1RA liraglutide counteracts the increased appetite during weight loss maintenance
Reported -9.4 · recomputed -3.3
Citations
The citation lists are queued
They are fetched later and appear here then.
References 45 · Cited by 42
Metadata
- Authors
- Jensen, S. B. K., Janus, C., Lundgren, J. R., Juhl, C. R., Sandsdal, R. M., Olsen, L. M., Andresen, A., Borg, S. A., Jacobsen, I. C., Finlayson, G., Stallknecht, B. M., Holst, J. J., Madsbad, S., & Torekov, S. S.
- Affiliations
- University of Copenhagen (DK)
- University of Leeds (GB)
- Hvidovre Hospital (DK)
- Corresponding author
- Torekov, Signe Sørensen
- ORCID
- Venue
- Nature Communications
- Published
- 2022-08-15
- Volume
- 13
- Issue
- 1
- Pages
- 4770-4770
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC9378667
- OpenAlex
- W4291511774
- Cited by
- 42
- References
- 45
- Citations by year
- 2026: 7 · 2025: 15 · 2024: 10 · 2023: 9 · 2022: 1
- FWCI
- 5.24
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Danish Diabetes Academy
- Novo Nordisk
- Helsefonden
- Faculty of Health and Medical Sciences, University of Western Australia
- Novo Nordisk Fonden (NNF15CC0018486, NNF20SA0064144, NNF16OC0019968, NNF20SA0064145, NNF15SA0018486, NNF20SA0064142)
- Det Sundhedsvidenskabelige Fakultet, Københavns Universitet
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Obesity, Physical Activity, Diet
- Keywords
- weight loss maintenance, obesity, liraglutide, GLP-1 receptor agonists, physical activity, sedentary behavior, dietary habits, postprandial appetite, cognitive restraint, weight regain, hypocaloric diet, energy expenditure
- MeSH terms
- Liraglutide, Adult, Double-Blind Method, Humans, Hypoglycemic Agents, Obesity, Weight Gain, Weight Loss, Exercise
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-04, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-04 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Exploratory analysis of eating-and physical activity-related outcomes from a randomized controlled trial for weight loss maintenance with exercise and liraglutide single or combination treatment. https://app.cochat.ai/papers/10.1038/s41467-022-32307-y
- The paper
- Jensen, S. B. K., Janus, C., Lundgren, J. R., Juhl, C. R., Sandsdal, R. M., Olsen, L. M., Andresen, A., Borg, S. A., Jacobsen, I. C., Finlayson, G., Stallknecht, B. M., Holst, J. J., Madsbad, S., & Torekov, S. S. (2022). Exploratory analysis of eating-and physical activity-related outcomes from a randomized controlled trial for weight loss maintenance with exercise and liraglutide single or combination treatment. Nature Communications. https://doi.org/10.1038/s41467-022-32307-y
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.